LVMH (MC.PA) enters late‑2025 after a reset in luxury demand. Over the last year, the stock fell 18.98% and trades near 492 (Sep 9, 2025), below its 200‑day moving average of 558.43 but close to the 50‑day at 481.76. Despite softer momentum—TTM revenue of 82.82B with quarterly revenue growth -4.50% and quarterly earnings growth -21.60%—profitability remains robust (13.26% net margin; 22.58% operating margin) and cash generation strong (TTM operating cash flow 19.52B; levered free cash flow 13.22B). Valuation sits at 22.55x trailing P/E and 20.24x forward, supported by a 2.62% forward dividend yield and 59.09% payout ratio. Recent headlines include an HSBC upgrade and signs of improving luxury sentiment, while brand initiatives such as Louis Vuitton’s high‑end beauty releases aim to deepen customer engagement for the next cycle.

With shares of GSK plc (GSK.L) trading around 1,464.5p as of 8 September 2025, the stock has spent six months oscillating between 1,294p and 1,534p. The company pairs defensive characteristics (beta 0.29) with a sizable income profile (forward dividend yield 4.34% on a 0.64 per‑share rate, ex‑div 14 August 2025). Fundamentals are mixed: trailing‑twelve‑month revenue stands at 31.63B with quarterly revenue growth of 1.30% year over year, yet quarterly earnings growth is a stronger 23.0%, supported by a 30.52% operating margin and 10.82% profit margin. Cash generation remains solid (operating cash flow 7.72B; levered free cash flow 5.48B), but balance‑sheet metrics warrant monitoring, with total debt of 17.35B, debt‑to‑equity of 120.90% and a current ratio of 0.87. This three‑year outlook assesses risks, catalysts and plausible paths for the share price.

As of September 2025, Roche’s investment case blends defensive cash generation with pipeline execution risk. The group reports trailing‑twelve‑month revenue of 63.49B and maintains robust profitability (operating margin 36.14%, profit margin 14.85%). Cash generation is solid (operating cash flow 19.28B; levered free cash flow 11.73B) alongside a 3.54% forward dividend yield, albeit with a relatively high payout ratio of 82.62%. Shares recently traded near 270.10, within a 52‑week range of 231.90–313.80, and sit close to the 200‑day moving average of 268.59 with a low beta of 0.18. Valuation signals a value tilt: forward P/E of 12.95 versus a trailing P/E of 23.36 and a PEG of 0.68. With quarterly revenue growth of 3.60% year over year and quarterly earnings growth of 18.40%, investors will focus on execution, capital allocation, pricing dynamics, and regulatory outcomes over the next three years.

As of (September 2025), Apple Inc. enters a pivotal product window with sturdy fundamentals and clear debate points for investors. The company reports trailing 12‑month revenue of 408.62B and net income of 99.28B, supported by a 29.99% operating margin and 24.30% profit margin. Shares recently closed at 239.69 (2025‑09‑01), sitting above the 50– and 200–day moving averages and up 8.50% over 52 weeks, though lagging the S&P 500’s 18.47%. Headlines highlight analyst support ahead of the next iPhone launch, ongoing antitrust scrutiny, and a renewed Watch‑related dispute, while Berkshire Hathaway has trimmed its stake. This note compiles the key facts, weighs recent developments, and lays out three‑year scenarios through September 2028, along with risks and catalysts that could move AAPL.